Dr. David A. Smoller served CEO of Sage Labs, a Life Science CRO based on Gene Editing technology until acquired By Horizon Discovery ( HZD.L) David continued at Horizon as Chief Business Officer and Board Member until December of 2015. Previous to those roles, Dr. Smoller was the Chief Scientific Officer of Sigma-Aldrich Corporation since February 2011 until August 3, 2012. Dr. Smoller served as the President of Research Biotech Business Unit of Sigma-Aldrich Corp. since July 5, 2007 and served as its Vice President of Research and Development since June 1, 2004.
Dr. Smoller served as President and Chief Executive Officer of ProteoPlex, a seed stage spinout focusing on functional genomics. He founded ProteoPlex in 2001 and led the St. Louis-based company through its product development and final acquisition by Merck KgA. In 1992, Dr. Smoller founded Genome Systems Inc., in St. Louis, which provided the scientific community with access to genome project-related technologies. Dr. Smoller stayed at the helm of Genome Systems, Inc. until it was acquired in 1996 by the Incyte Corporation. Dr. Smoller joined Incyte as Vice President eventually becoming Senior Vice President, overseeing the Global Genomics, Business Unit.
Dr. Smoller earned a doctorate degree in Molecular Biology and a bachelor’s degree in Biology from Emory University in Atlanta, Georgia. He completed a postdoctoral fellowship from Washington University in the Drosophila Genome project and a postdoctoral fellowship at Monsanto Corporation.
David Kingsley is Managing Member of PDDK LLC, a real estate development company with a focus on distressed assets in Puerto Rico. Prior to that he was Senior Portfolio Manager at Horizon Kinetics LLC, where he managed the Horizon Credit Opportunities Master Fund, Ltd. Prior to Horizon Kinetics, Mr. Kingsley was a Portfolio Manager at Kingsley Capital, Scottenfeld Associates, and Teleos Asset Management. Mr. Kingsley received his BS/BA degree from Washington University in St. Louis in 1991.
Charlie Bolten is Vice President of BioGenerator, where he has served since 2009. Charlie participates in all aspects of technology commercialization at BioGenerator. At the time of his recruitment to BioGenerator, Charlie held the position of Principal Scientist and Project Leader in the Pfizer Exploratory Immunobiology group, where he led a reverse pharmacology collaboration with PTC Therapeutics focusing on post-transcriptional regulation of T cell cytokines and was the Research Project Leader for small molecule discovery program targeting an effector T cell subtype-selective receptor. Example BioGenerator portfolio companies for Charlie include Adarza, Vasculox, Medibeacon, Confluence Life Sciences, Arvegenix, and Antegrin.
Dr. Edward J. Weinstein was co-Founder and President of SAGE Labs, a life science contract research organization with a focus on genetic engineering, until it was acquired by Horizon Discovery in 2014. Edward continued at Horizon as President of the Research Services business unit until 2016. Prior to those roles, Edward served as Manager of R&D and Director of Operations in the Research Biotechnology business unit of Sigma-Aldrich. He has also worked in the pharmaceutical industry, leading molecular profiling portfolios for both Merck and Pfizer. Dr. Weinstein has earned a Ph.D. in genetics from Harvard University, a Masters of Medical Science from Harvard Medical School and bachelor degrees in Chemistry and Cellular-Molecular Biology from the University of Michigan.